The overall objective of this proposal is to understand the role of orbital fibroblasts in the pathogenesis of thyroid-associated ophthalmopathy (TAO), the orbital manifestation of Graves' disease (GD). There are currently no effective therapies for this potentially sight-threatening disease. We have found that GD fibroblasts express excessive levels of insulin-like growth factor-1 receptor (IGF-1R), which is activated by GD-specific antibodies (GD-IgG). This leads to expression ofIL-16 and RANTES, two T lymphocyte chemo attractants. Moreover, GD-IgG provokes the nuclear accumulation of lGF-1Ralpha, in GD fibroblasts. Control fibroblasts fail to respond to GD-IgG. We hypothesize that IGF-1R activation by GD-IgG and consequent induction oflL-16 and RANTES underlie T cell infiltration of the orbit and other connective tissue in GD. On the other hand, orbital fibroblasts exhibit unique phenotypic attributes, including exaggerated responses to cytokines such as IL-1beta. These include the induction oflL-6, an important B cell activator and enzymes for hyaluronan and PGE2 production. We hypothesize that hyaluronan, PGEe and IL-6 synthesis by orbital fibroblasts leads to localized orbital manifestations of TAO. We propose to 1) define the molecular events surrounding the activation of lGF-1R by GD-IgG and the resulting signaling that leads to IL-16 and RANTES expression by studying IGF-1R expression, and signaling and characterizing the GD-IgG/IGF- 1R interactions 2) characterize the anatomic site-specific induction in orbital fibroblasts of IL-6 by IL-1beta by assessing gene transcription, mRNA stability, and signal transduction 3) assess the expression and induction by IL-1beta of phospholipase A2 (sPLA2 and cPLAz) in orbital fibroblasts by determining whether gene transcription and/or mRNA stability are involved and whether PLA2 expression and activity influences levels of other key prostanoid biosynthetic enzymes. Our results to date, we believe, represent a new disease paradigm for TAO. Moreover, the proposed studies represent logical extensions of our recent findings and should lead to the identity of mechanism-based therapeutic targets for this vexing disease.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
2R01EY008976-13
Application #
6868733
Study Section
Special Emphasis Panel (ZRG1-AED (01))
Program Officer
Shen, Grace L
Project Start
1992-12-01
Project End
2009-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
13
Fiscal Year
2005
Total Cost
$332,059
Indirect Cost
Name
La Biomed Research Institute/ Harbor UCLA Medical Center
Department
Type
DUNS #
069926962
City
Torrance
State
CA
Country
United States
Zip Code
90502
Fernando, Roshini; Grisolia, Ana Beatriz Diniz; Lu, Yan et al. (2018) Slit2 Modulates the Inflammatory Phenotype of Orbit-Infiltrating Fibrocytes in Graves' Disease. J Immunol 200:3942-3949
Smith, Terry J (2018) Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. Annu Rev Pharmacol Toxicol :
Mohyi, Michelle; Smith, Terry J (2018) IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol 61:T29-T43
Lu, Yan; Atkins, Stephen J; Fernando, Roshini et al. (2018) CD34- Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-? Expression in CD34+ Fibroblasts and Fibrocytes. Invest Ophthalmol Vis Sci 59:2615-2622
Smith, Terry J (2018) New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. F1000Res 7:134
Smith, Terry J; Hegedüs, Laszlo (2017) Graves' Disease. N Engl J Med 376:185
Citterio, Cintia E; Veluswamy, Balaji; Morgan, Sarah J et al. (2017) De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone. J Biol Chem 292:15434-15444
Smith, Terry J; Kahaly, George J; Ezra, Daniel G et al. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 376:1748-1761
Smith, Terry (2017) TSHR as a therapeutic target in Graves' disease. Expert Opin Ther Targets 21:427-432
Fernando, Roshini; Placzek, Ekaterina; Reese, Edmund A et al. (2017) Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab 102:776-785

Showing the most recent 10 out of 138 publications